Leukemia

Articles

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.

Despite Improved Survival Rates in T-ALL, Investigators Seek Further Improvements Through Immunotherapeutics

A recent study provides evidence showing that focal 22q11.22 deletions may be correlated with poor outcomes in patients with pediatric B-cell acute lymphoblastic leukemia with alterations in IKZF1.

Focal 22q11.22 Deletions Associated With Poor Outcomes in Pediatric B-Cell Acute Lymphoblastic Leukemia With IKZF1 Alterations

Pediatric patients with low-risk acute lymphoblastic leukemia may be able to omit treatment with vincristine and dexamethasone pulse therapy after the first year of treatment.

Vincristine/Dexamethasone Pulse Therapy May be Omitted After 1 Year of Treatment in Pediatric Acute Lymphoblastic Leukemia

Compared with anti-thymocyte globulin, post-transplant cyclophosphamide appears to more successfully prevent graft-versus-host disease in patients with acute lymphoblastic leukemia, resulting in a lower incidence of relapse and improved survival.

Post-Transplant Cyclophosphamide Appears to be a Promising Prophylactic Treatment Against GvHD in Acute Lymphoblastic Leukemia

A study published in Lancet Oncology indicated that children with low-risk acute lymphoblastic leukemia may be able to safely omit pulse therapy after 1-year of treatment. 


Pulse Therapy Can Be Omitted for in Pediatric Low-Risk Acute Lymphoblastic Leukemia After 1 Year of Treatment

Pediatric and adolescent patients with acute lymphoblastic leukemia experienced similar outcomes when treated with either calaspargase pegol or pegaspargase. 

Calaspargase and Pegaspargase Elicit Similar Responses, Toxicity Profiles in Pediatric and Adolescent ALL

Videos

Dr Stein elaborates on some practical considerations for the use of venetoclax and hypomethylating agents for the treatment of patients with chemotherapy-ineligible acute myeloid leukemia.

Practical Considerations for Venetoclax Plus HMA for Chemotherapy-Ineligible AML

Patients with Philadelphia chromosome–negative acute lymphocytic leukemia who have hypersensitivity to pegylated asparaginase may benefit from eryaspase treatment. 

FDA Grants Fast Track Designation to Eryaspase in Asparaginase Hypersensitive ALL

The phase 2 GIMEMA LAL1913 trial identified poor outcomes and increased minimal residual disease persistence among patients with Philadelphia-like acute lymphoblastic leukemia.

Increased MRD Persistence, Lower Rates of Remission and Survival Seen With Philadelphia-Like ALL

A new study has adapted CAR to look more human to the body, which will then in turn yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Acute Lymphoblastic Leukemia | Topics